A NYT article has Wall Street abuzz today with whispers of non-profit hospital groups creating a new generics maker or partnering with third party manufacturers.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.
Crypto-related GPU sales appear to be more massive than AMD and NVDA had expected in 4Q17; here’s why Susquehanna’s Christopher Rolland says this could be an issue.
Oppenheimer’s Ittai Kidron asks where can IBM “go from here” following two consecutive years of gross margin downturns in every segment?
Cantor’s Joseph Foresi highlights some positives in IBM’s favor approaching tonight’s quarterly results, but still sees more downside risk than upside gain to shares.
RBC Capital’s Elvira Scotto projects 15% in return potential for KMI stock following the 4Q earnings showcase.